Efficacy and Safety of Immunotherapies in Refractory Myasthenia Gravis: A Systematic Review and Meta-Analysis
Introduction: Approximately 10–20% of patients WITH myasthenia gravis (MG) are refractory to conventional immunotherapies. The purpose of this study was to conduct a systematic review and meta-analysis to explore the optimal therapies for refractory MG.Method: Correlative studies were performed thro...
Guardado en:
Autores principales: | Xuelin Feng, Zubiao Song, Mengli Wu, Yanmei Liu, Sushan Luo, Chongbo Zhao, Weixi Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/7271f06cc9e1455cada1fd974c4fdddf |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical features, treatment and prognosis of MuSK antibody-associated myasthenia gravis in Northwest China: a single-centre retrospective cohort study
por: Sijia Zhao, et al.
Publicado: (2021) -
Miastenia gravis refractaria con buena respuesta a rituximab. Caso clínico
por: Suárez H.,Felipe, et al.
Publicado: (2020) -
Fetal Surveillance in Pregnancies with Myasthenia Gravis
por: Brîndușa Ana Cimpoca-Raptis, et al.
Publicado: (2021) -
Comorbid Autoimmune Diseases in Patients With Myasthenia Gravis: A Retrospective Cross-Sectional Study of a Chinese Cohort
por: Jianquan Shi, et al.
Publicado: (2021) -
Research of antibodies to the acetylcholine receptors in patients with myasthenia gravis
por: T. V. Romanova
Publicado: (2013)